Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	38.78	62.48	52.23	135.19	190.46	85.92
Short-Term Investments	31.16	46.24	139.21	142.78	38.16	163.32
Cash & Short-Term Investments	69.94	108.71	191.44	277.97	228.62	249.24
Cash Growth	-52.93%	-43.21%	-31.13%	21.59%	-8.28%	-4.85%
Receivables	35.24	30.77	27.96	54.89	23.9	12.88
Inventory	4.77	4.74	3.04	4.22	4.11	2.64
Prepaid Expenses	10.29	12.25	10.81	12.02	12.64	9.29
Restricted Cash	-	0.03	0.66	1.06	6.35	2.48
Total Current Assets	120.24	156.49	233.92	350.16	275.61	276.53
Property, Plant & Equipment	5.8	6.28	4.88	7.38	9.56	11.58
Long-Term Investments	-	-	-	-	-	24.22
Long-Term Accounts Receivable	-	-	-	-	19.51	-
Other Long-Term Assets	1.67	1.64	1.64	0.63	0.64	0.72
Total Assets	127.71	164.42	240.44	358.17	305.31	313.05
Accounts Payable	5.87	5.11	3.12	2.77	1.6	4.45
Accrued Expenses	57.17	60.65	61.39	58.42	69.12	52.93
Short-Term Debt	24.46	24.43	-	-	-	-
Current Portion of Leases	0.93	0.44	3.31	2.87	2.32	1.92
Current Unearned Revenue	-	-	-	-	-	0.3
Other Current Liabilities	1.94	1.64	1.65	1.85	0.68	0.61
Total Current Liabilities	90.37	92.26	69.48	65.91	73.72	60.2
Long-Term Debt	228.33	236.45	303.4	302.82	302.29	191.02
Long-Term Leases	6.49	6.71	2.79	6.1	8.97	11.29
Other Long-Term Liabilities	8.41	15.01	0.98	-	-	-
Total Liabilities	333.6	350.44	376.64	374.83	384.98	262.5
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,381	1,378	1,351	1,328	1,099	1,120
Retained Earnings	-1,587	-1,563	-1,487	-1,344	-1,179	-1,070
Comprehensive Income & Other	-0.32	-0.36	-0.16	-0.64	0.19	0.52
Shareholders' Equity	-205.88	-186.02	-136.21	-16.66	-79.67	50.55
Total Liabilities & Equity	127.71	164.42	240.44	358.17	305.31	313.05
Total Debt	260.2	268.02	309.5	311.79	313.58	204.22
Net Cash (Debt)	-190.26	-159.31	-118.05	-33.83	-84.96	45.02
Net Cash Growth	-	-	-	-	-	-29.28%
Net Cash Per Share	-22.88	-18.84	-15.50	-6.20	-16.94	9.37
Filing Date Shares Outstanding	8.64	8.42	7.67	7.56	5.28	4.98
Total Common Shares Outstanding	8.57	8.41	7.66	7.55	5.05	4.93
Working Capital	29.87	64.23	164.44	284.25	201.89	216.33
Book Value Per Share	-24.03	-22.11	-17.78	-2.21	-15.78	10.26
Tangible Book Value	-205.88	-186.02	-136.21	-16.66	-79.67	50.55
Tangible Book Value Per Share	-24.03	-22.11	-17.78	-2.21	-15.78	10.26
Machinery	-	2.21	2.29	2.33	2.25	1.97
Leasehold Improvements	-	4.88	4.88	5.45	5.45	5.44

Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q